Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / Fund iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer Blackrock
Entity holding fund iShares VII Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF Ticker CUS1(GBX) LSE
ETF Ticker CUSS(USD) LSE
ETF Ticker SXRG(EUR) F
ETF Ticker CSUSS.MI(EUR) CXE
ETF Ticker CSUSSz(USD) CXE
ETF Ticker CUSS.LS(USD) CXE
ETF Ticker CSUSS(EUR) ETF Plus
ETF Ticker CUS1.L(GBP) LSE
ETF Ticker CUSS.L(GBP) LSE

Holdings detail for KYMR

Stock Name	Kymera Therapeutics Inc
Ticker	KYMR(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US5015751044

Show aggregate KYMR holdings

News associated with KYMR

Kymera Therapeutics (NASDAQ:KYMR) Now Covered by Barclays: Barclays initiated coverage on shares of Kymera Therapeutics (NASDAQ:KYMR – Free Report) in a report published on Wednesday, Marketbeat reports. The firm issued an overweight rating and a $60.00 price target on the stock. Other research analysts have also issued research reports about the stock. BTIG Research reiterated a “buy” rating and set a $59.00 […] - 2025-09-18 05:13:29
Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $58.76: Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has received an average rating of “Buy” from the nineteen analysts that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, fifteen have given a buy recommendation and three have assigned a strong buy recommendation to the company. The […] - 2025-09-08 02:50:52
Wednesday's ETF with Unusual Volume: FYC: The First Trust Small Cap Growth AlphaDEX Fund ETF is seeing unusually high volume in afternoon trading Wednesday, with over 111,000 shares traded versus three month average volume of about 27,000. Shares of FYC were up about 0.4% on the day. Components of that ETF with the hi - 2025-08-27 13:50:50
Kymera Therapeutics (NASDAQ:KYMR) Rating Lowered to Sell at Wall Street Zen: Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday. Other analysts have also recently issued reports about the stock. Oppenheimer restated an “outperform” rating and set a $53.00 target price (down from $56.00) on […] - 2025-08-18 04:46:57
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $59.11 Consensus PT from Analysts: Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has earned an average recommendation of “Buy” from the twenty brokerages that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating, sixteen have given a buy rating and three have assigned a strong buy rating to the company. […] - 2025-08-14 02:32:51
Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Down Following Weak Earnings: Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report)’s stock price gapped down prior to trading on Monday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $40.62, but opened at $38.16. Kymera Therapeutics shares last traded at $39.34, with a volume of 134,694 shares trading hands. The company reported […] - 2025-08-13 02:17:07
Notable Two Hundred Day Moving Average Cross - KYMR: In trading on Monday, shares of Kymera Therapeutics Inc (Symbol: KYMR) crossed below their 200 day moving average of $39.13, changing hands as low as $36.65 per share. Kymera Therapeutics Inc shares are currently trading off about 2.8% on the day. The chart below shows the one - 2025-08-11 12:49:18
Kymera Revenue Drops 55 Percent in Q2: Key PointsGAAP revenue declined sharply from $25.7 million in Q2 2024 to $11.5 million in Q2 2025, missing analyst expectations by 48.4% for Q2 2025 (GAAP). - 2025-08-11 08:28:41
Kymera Therapeutics (NASDAQ:KYMR) Now Covered by Analysts at Morgan Stanley: Morgan Stanley assumed coverage on shares of Kymera Therapeutics (NASDAQ:KYMR – Free Report) in a research report released on Thursday morning. The brokerage issued an overweight rating and a $70.00 price objective on the stock. A number of other research analysts also recently issued reports on the company. Guggenheim reissued a “buy” rating and issued […] - 2025-07-04 04:59:46
Bvf Partners L. P/Il Buys 317,167 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stock: Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) Director Bvf Partners L. P/Il purchased 317,167 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, June 30th. The shares were bought at an average cost of $44.00 per share, for a total transaction of $13,955,348.00. Following the completion of the transaction, the director […] - 2025-07-03 05:26:56
Wells Fargo & Company Lowers Kymera Therapeutics (NASDAQ:KYMR) Price Target to $53.00: Kymera Therapeutics (NASDAQ:KYMR – Free Report) had its target price trimmed by Wells Fargo & Company from $57.00 to $53.00 in a report released on Thursday morning,Benzinga reports. They currently have an overweight rating on the stock. Other equities analysts have also issued research reports about the company. Wall Street Zen upgraded Kymera Therapeutics from […] - 2025-06-27 04:46:43
We Did The Math TMSL Can Go To $38: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-10 08:53:34
Kymera Therapeutics (NASDAQ:KYMR) Upgraded by Bank of America to “Buy” Rating: Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) was upgraded by research analysts at Bank of America from a “neutral” rating to a “buy” rating in a research note issued to investors on Monday, Marketbeat.com reports. The firm currently has a $51.00 price target on the stock. Bank of America‘s price objective points to a potential […] - 2025-06-04 02:50:56
Kymera Therapeutics (NASDAQ:KYMR) Sees Large Volume Increase on Analyst Upgrade: Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) shares saw strong trading volume on Tuesday after JPMorgan Chase & Co. raised their price target on the stock from $57.00 to $64.00. JPMorgan Chase & Co. currently has an overweight rating on the stock. 961,245 shares changed hands during mid-day trading, an increase of 62% from […] - 2025-06-04 02:01:25
Universal Beteiligungs und Servicegesellschaft mbH Invests $4.61 Million in Kymera Therapeutics, Inc. (NASDAQ:KYMR): Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 114,587 shares of the company’s stock, valued at approximately $4,610,000. Universal Beteiligungs und […] - 2025-06-02 05:36:54
Bank of America Corp DE Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR): Bank of America Corp DE cut its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 43.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,260 shares of the company’s stock after selling 48,772 shares during the quarter. Bank of America […] - 2025-06-02 04:38:48
BNP Paribas Financial Markets Makes New $396,000 Investment in Kymera Therapeutics, Inc. (NASDAQ:KYMR): BNP Paribas Financial Markets acquired a new stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 9,838 shares of the company’s stock, valued at approximately $396,000. Several other hedge […] - 2025-05-26 04:24:47
D. E. Shaw & Co. Inc. Lowers Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR): D. E. Shaw & Co. Inc. cut its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 56.1% during the fourth quarter, Holdings Channel reports. The institutional investor owned 82,578 shares of the company’s stock after selling 105,619 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Kymera Therapeutics were worth […] - 2025-05-19 05:12:56
Northern Trust Corp Grows Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR): Northern Trust Corp raised its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 14.0% during the 4th quarter, Holdings Channel.com reports. The firm owned 437,833 shares of the company’s stock after acquiring an additional 53,658 shares during the quarter. Northern Trust Corp’s holdings in Kymera Therapeutics were worth $17,614,000 as of […] - 2025-05-15 05:38:47
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Comerica Bank: Comerica Bank cut its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 45.8% in the fourth quarter, Holdings Channel.com reports. The firm owned 20,631 shares of the company’s stock after selling 17,442 shares during the quarter. Comerica Bank’s holdings in Kymera Therapeutics were worth $830,000 at the end of the most recent reporting […] - 2025-05-14 05:19:05
Guggenheim Reaffirms “Buy” Rating for Kymera Therapeutics (NASDAQ:KYMR): Kymera Therapeutics (NASDAQ:KYMR – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a research report issued on Monday,Benzinga reports. They presently have a $52.00 price target on the stock. Guggenheim’s price objective points to a potential upside of 66.99% from the company’s current price. A number of […] - 2025-05-14 03:10:53
Tower Research Capital LLC TRC Increases Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR): Tower Research Capital LLC TRC increased its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 95.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 4,812 shares of the company’s stock after purchasing an additional 2,350 shares during the […] - 2025-05-06 05:16:52
Marshall Wace LLP Sells 110,846 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR): Marshall Wace LLP decreased its holdings in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 94.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,835 shares of the company’s stock after selling 110,846 shares during the period. Marshall Wace LLP’s holdings in […] - 2025-05-05 05:04:51
Wells Fargo & Company MN Has $883,000 Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR): Wells Fargo & Company MN grew its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 51.8% during the fourth quarter, Holdings Channel reports. The firm owned 21,939 shares of the company’s stock after acquiring an additional 7,487 shares during the quarter. Wells Fargo & Company MN’s holdings in Kymera Therapeutics were worth $883,000 […] - 2025-05-01 04:35:02
Franklin Resources Inc. Acquires 8,927 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR): Franklin Resources Inc. raised its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 30.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 38,367 shares of the company’s stock after acquiring an additional 8,927 shares during the period. Franklin Resources Inc. owned approximately 0.06% […] - 2025-04-15 05:32:48
Alliancebernstein L.P. Cuts Stock Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR): Alliancebernstein L.P. lessened its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 29.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 88,246 shares of the company’s stock after selling 36,368 shares during the quarter. Alliancebernstein L.P.’s holdings in Kymera Therapeutics were worth $3,550,000 as of its most recent filing with the […] - 2025-04-15 04:50:48
Norges Bank Invests $3.67 Million in Kymera Therapeutics, Inc. (NASDAQ:KYMR): Norges Bank acquired a new position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 91,231 shares of the company’s stock, valued at approximately $3,670,000. Several other large investors have also bought and […] - 2025-04-11 05:12:59
Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $56.36: Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) has earned an average rating of “Moderate Buy” from the fifteen research firms that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-04-11 03:08:47
Vanguard Group Inc. Acquires 133,546 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR): Vanguard Group Inc. grew its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 2.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 4,887,312 shares of the company’s stock after purchasing an additional 133,546 shares during the quarter. Vanguard Group Inc. owned about 0.08% of Kymera Therapeutics worth $196,617,000 […] - 2025-04-07 04:34:48
Teacher Retirement System of Texas Increases Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR): Teacher Retirement System of Texas raised its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 35.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 11,490 shares of the company’s stock after purchasing an additional 3,026 shares during the period. Teacher Retirement System of Texas’ holdings in Kymera Therapeutics were worth […] - 2025-04-01 04:40:45

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc KYMR holdings

Date	Number of KYMR Shares Held	Base Market Value of KYMR Shares	Local Market Value of KYMR Shares	Change in KYMR Shares Held	Change in KYMR Base Value	Current Price per KYMR Share Held	Previous Price per KYMR Share Held
2025-09-26 (Friday)	21,934	USD 1,233,788	USD 1,233,788
2025-09-25 (Thursday)	21,934	USD 1,178,623	USD 1,178,623	0	USD 27,088	USD 53.735	USD 52.5
2025-09-24 (Wednesday)	21,934	USD 1,151,535	USD 1,151,535
2025-09-17 (Wednesday)	21,792	USD 1,048,631	USD 1,048,631	0	USD -14,383	USD 48.12	USD 48.78
2025-09-16 (Tuesday)	21,792	USD 1,063,014	USD 1,063,014
2025-09-12 (Friday)	21,650	USD 1,017,334	USD 1,017,334
2025-09-11 (Thursday)	21,650	USD 1,000,230	USD 1,000,230

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of KYMR by Blackrock for IE00B3VWM098

Show aggregate share trades of KYMR

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-08-21 SELL -71 42.590* 38.48 Profit of 2,732 on sale
2025-07-31 BUY 213 43.750* 38.43
2025-06-30 SELL -142 43.640* 37.58 Profit of 5,337 on sale
2025-06-25 SELL -71 46.470* 37.42 Profit of 2,657 on sale
2025-06-20 SELL -142 45.870* 37.22 Profit of 5,286 on sale
2025-05-30 SELL -8,533 29.640* 36.25 Profit of 309,298 on sale
2025-05-23 BUY 100 29.490* 36.54
2025-05-19 SELL -100 30.200* 36.75 Profit of 3,675 on sale
2025-05-15 SELL -300 30.020* 36.86 Profit of 11,059 on sale
2025-05-12 SELL -100 32.170* 37.02 Profit of 3,702 on sale
2025-05-09 SELL -100 30.070* 37.09 Profit of 3,709 on sale
2025-04-30 SELL -100 34.270* 37.41 Profit of 3,741 on sale
2025-04-24 SELL -200 33.560* 37.57 Profit of 7,513 on sale
2025-04-17 SELL -100 25.970* 38.09 Profit of 3,809 on sale
2025-04-15 SELL -300 25.460* 38.37 Profit of 11,511 on sale
2025-04-14 SELL -300 25.430* 38.51 Profit of 11,554 on sale
2025-04-09 SELL -400 23.950* 39.02 Profit of 15,610 on sale
2025-04-07 SELL -700 22.010* 39.43 Profit of 27,602 on sale
2025-04-04 SELL -1,000 22.070* 39.64 Profit of 39,636 on sale
2025-03-31 BUY 100 27.370* 40.12
2025-03-19 SELL -200 33.870* 41.01 Profit of 8,202 on sale
2025-03-14 SELL -600 34.370* 41.29 Profit of 24,776 on sale
2025-03-13 SELL -200 33.450* 41.41 Profit of 8,281 on sale
2025-03-12 SELL -3,400 35.100* 41.50 Profit of 141,090 on sale
2025-03-07 SELL -200 32.890* 41.88 Profit of 8,376 on sale
2025-03-06 SELL -300 32.540* 42.02 Profit of 12,607 on sale
2025-03-03 SELL -100 30.170* 42.56 Profit of 4,256 on sale
2025-02-28 BUY 2,877 31.350* 42.75
2025-02-26 SELL -91 35.360* 43.09 Profit of 3,921 on sale
2025-02-25 SELL -273 34.710* 43.23 Profit of 11,802 on sale
2025-02-18 BUY 455 37.130* 43.83
2025-02-13 BUY 91 36.630* 44.25
2025-02-12 BUY 91 35.150* 44.44
2025-02-11 BUY 273 34.410* 44.65
2025-02-06 BUY 819 39.040* 45.13
2025-01-27 BUY 91 41.220* 46.31
2024-12-30 BUY 455 39.320* 46.81
2024-12-06 BUY 364 46.670* 46.98
2024-12-05 BUY 91 44.080* 47.08
2024-12-04 BUY 455 46.020* 47.12
2024-11-29 BUY 455 46.850* 47.11
2024-11-27 BUY 364 46.860* 47.14
2024-11-26 BUY 91 45.980* 47.19
2024-11-25 BUY 4,647 47.020* 47.20
2024-11-21 BUY 385 43.510* 47.51
2024-11-20 BUY 231 44.050* 47.70
2024-11-18 BUY 924 42.410* 48.33
2024-11-12 BUY 616 50.000* 48.22
2024-11-08 BUY 385 50.950* 48.03
2024-11-07 BUY 1,155 49.860* 47.89
2024-11-06 BUY 154 49.480* 47.75
2024-10-31 BUY 77 46.170* 48.21
Market high and low price is on the date.

Date	Action	Quantity	Likely Trade Price	Average Price previous trades
2025-08-21	SELL	-71	42.590*	38.48 Profit of 2,732 on sale
2025-07-31	BUY	213	43.750*	38.43
2025-06-30	SELL	-142	43.640*	37.58 Profit of 5,337 on sale
2025-06-25	SELL	-71	46.470*	37.42 Profit of 2,657 on sale
2025-06-20	SELL	-142	45.870*	37.22 Profit of 5,286 on sale
2025-05-30	SELL	-8,533	29.640*	36.25 Profit of 309,298 on sale
2025-05-23	BUY	100	29.490*	36.54
2025-05-19	SELL	-100	30.200*	36.75 Profit of 3,675 on sale
2025-05-15	SELL	-300	30.020*	36.86 Profit of 11,059 on sale
2025-05-12	SELL	-100	32.170*	37.02 Profit of 3,702 on sale
2025-05-09	SELL	-100	30.070*	37.09 Profit of 3,709 on sale
2025-04-30	SELL	-100	34.270*	37.41 Profit of 3,741 on sale
2025-04-24	SELL	-200	33.560*	37.57 Profit of 7,513 on sale
2025-04-17	SELL	-100	25.970*	38.09 Profit of 3,809 on sale
2025-04-15	SELL	-300	25.460*	38.37 Profit of 11,511 on sale
2025-04-14	SELL	-300	25.430*	38.51 Profit of 11,554 on sale
2025-04-09	SELL	-400	23.950*	39.02 Profit of 15,610 on sale
2025-04-07	SELL	-700	22.010*	39.43 Profit of 27,602 on sale
2025-04-04	SELL	-1,000	22.070*	39.64 Profit of 39,636 on sale
2025-03-31	BUY	100	27.370*	40.12
2025-03-19	SELL	-200	33.870*	41.01 Profit of 8,202 on sale
2025-03-14	SELL	-600	34.370*	41.29 Profit of 24,776 on sale
2025-03-13	SELL	-200	33.450*	41.41 Profit of 8,281 on sale
2025-03-12	SELL	-3,400	35.100*	41.50 Profit of 141,090 on sale
2025-03-07	SELL	-200	32.890*	41.88 Profit of 8,376 on sale
2025-03-06	SELL	-300	32.540*	42.02 Profit of 12,607 on sale
2025-03-03	SELL	-100	30.170*	42.56 Profit of 4,256 on sale
2025-02-28	BUY	2,877	31.350*	42.75
2025-02-26	SELL	-91	35.360*	43.09 Profit of 3,921 on sale
2025-02-25	SELL	-273	34.710*	43.23 Profit of 11,802 on sale
2025-02-18	BUY	455	37.130*	43.83
2025-02-13	BUY	91	36.630*	44.25
2025-02-12	BUY	91	35.150*	44.44
2025-02-11	BUY	273	34.410*	44.65
2025-02-06	BUY	819	39.040*	45.13
2025-01-27	BUY	91	41.220*	46.31
2024-12-30	BUY	455	39.320*	46.81
2024-12-06	BUY	364	46.670*	46.98
2024-12-05	BUY	91	44.080*	47.08
2024-12-04	BUY	455	46.020*	47.12
2024-11-29	BUY	455	46.850*	47.11
2024-11-27	BUY	364	46.860*	47.14
2024-11-26	BUY	91	45.980*	47.19
2024-11-25	BUY	4,647	47.020*	47.20
2024-11-21	BUY	385	43.510*	47.51
2024-11-20	BUY	231	44.050*	47.70
2024-11-18	BUY	924	42.410*	48.33
2024-11-12	BUY	616	50.000*	48.22
2024-11-08	BUY	385	50.950*	48.03
2024-11-07	BUY	1,155	49.860*	47.89
2024-11-06	BUY	154	49.480*	47.75
2024-10-31	BUY	77	46.170*	48.21

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of KYMR

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	309,046	3,591	440,760	70.1%
2025-09-18	223,301	7,626	444,002	50.3%
2025-09-17	307,071	1,955	434,446	70.7%
2025-09-16	234,451	3,639	317,172	73.9%
2025-09-15	202,005	2,548	260,745	77.5%
2025-09-12	139,517	307	207,721	67.2%
2025-09-11	124,303	300	190,842	65.1%
2025-09-10	142,312	0	254,156	56.0%
2025-09-09	112,495	0	199,835	56.3%
2025-09-08	125,694	0	243,191	51.7%
2025-09-05	136,137	4,123	196,490	69.3%
2025-09-04	212,656	0	413,751	51.4%
2025-09-03	150,086	0	325,025	46.2%
2025-09-02	173,311	0	513,103	33.8%
2025-08-29	72,127	27	174,510	41.3%
2025-08-28	69,778	5	227,826	30.6%
2025-08-27	147,866	0	265,304	55.7%
2025-08-26	119,682	471	140,473	85.2%
2025-08-25	76,967	0	113,682	67.7%
2025-08-22	135,604	2,740	192,354	70.5%
2025-08-21	125,730	0	181,377	69.3%
2025-08-20	119,391	0	150,089	79.5%
2025-08-19	129,153	0	198,058	65.2%
2025-08-18	176,394	200	254,714	69.3%
2025-08-15	269,401	700	341,184	79.0%
2025-08-14	273,156	1,009	390,021	70.0%
2025-08-13	208,680	0	267,116	78.1%
2025-08-12	236,621	94	360,461	65.6%
2025-08-11	430,146	0	664,953	64.7%
2025-08-08	189,815	0	384,750	49.3%
2025-08-07	128,981	0	203,181	63.5%
2025-08-06	90,389	3	157,957	57.2%
2025-08-05	36,394	0	64,189	56.7%
2025-08-04	76,200	0	104,248	73.1%
2025-08-01	89,233	0	115,453	77.3%
2025-07-31	105,933	800	152,574	69.4%
2025-07-30	129,479	0	204,164	63.4%
2025-07-29	155,236	0	232,322	66.8%
2025-07-28	161,674	0	233,442	69.3%
2025-07-25	78,056	80	164,296	47.5%
2025-07-24	71,971	0	91,137	79.0%
2025-07-23	60,582	0	90,359	67.0%
2025-07-22	72,103	0	157,347	45.8%
2025-07-21	144,850	1,363	258,325	56.1%
2025-07-18	170,167	80	221,778	76.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE